NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT00036790 2019-12-17Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced CancerUniversity of Wisconsin, MadisonPhase 1 Completed
NCT01205503 2016-02-24Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) ReleaseUniversity of KentuckyPhase 2 Completed32 enrolled 24 charts